PMC Isochem

What PMC Isochem does

PMC Isochem is a French pharmaceutical Contract Development and Manufacturing Organization (CDMO) headquartered in Vert-Le-Petit, operating three cGMP production sites within 60 miles of Paris with a combined 240 m³ of reaction capacity and 230+ employees. The company was founded in 1980 on SNPE's chemical heritage and was acquired in 2018 by PMC Group International, where it now operates as a wholly owned subsidiary of PMC Group France. Its core CDMO offering spans custom manufacturing of active pharmaceutical ingredients (APIs), intermediates, excipients, and polymers under cGMP conditions, supported by specialized capabilities in hazardous chemistry: phosgenation (50 years of know-how), hydrogenation (22 m³ capacity, 40-bar Biazzi), halogenation at scales up to 10,000L, cryogenic reactions at -70°C / 3000L, and cGMP wiped-film distillation.

The product portfolio combines custom manufacturing with a substantial catalog business: approximately 160 pharmaceutical intermediates, around 60 cataloged N-CarboxyAnhydrides (NCAs) and UNCAs, generic APIs, the ISODEL® Vitamin E TPGS excipient line (in multiple PEG molecular weights), GMP polyamino acids (Poly-L-Lysine, Poly-L-Glutamic acid, Polysarcosine), and a niche anti-scratch varnish line for optical applications. The ISODEL® brand was launched in 2019 to consolidate the company's drug-delivery positioning.

PMC Isochem generates revenue through a mix of project-based CDMO contracts (priced via RFP) and catalog product sales, sold directly to enterprise pharmaceutical companies via B2B engagement, contact forms, and industry-event presence (DCAT Week, CHEM BIO Symposium). The company holds a strategic partnership with Polypeptide Therapeutic Solutions (signed March 2018) in therapeutic and cosmetic polypeptides. In January 2026, the company extended its offering into contract research (CRO) services covering analytical development and nanoformulation, signaling an upstream move in the pharmaceutical services value chain. All three production sites are GMP US-FDA audited, and the company holds GDPR-compliant data practices as a French-domiciled entity.

Name

PMC Isochem

Legal name

PMC ISOCHEM

Website

https://pmcisochem.fr

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

101–250 employees

Short description

PMC Isochem is a French pharmaceutical CDMO operating three cGMP sites with 240 m³ of reaction capacity, specializing in custom manufacturing of APIs, intermediates, excipients, and polyamino acids under hazardous chemistry capabilities, serving enterprise pharmaceutical customers globally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development & Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule API Commercial Manufacturing (HLAGAHAB), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical CDMO services
• Custom API manufacturing
• Pharmaceutical intermediates
• Drug delivery materials
• CGMP contract manufacturing

Headquarters

HQ city

Vert-le-petit

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Custom Development and Manufacturing (CDMO): Custom manufacturing services for pharmaceutical companies including custom APIs, intermediates, excipients, and polymers under cGMP conditions. Services include R&D, process development, scale-up, and full plant-scale production.
2. Catalogue Products - NCA/UNCA: Sale of N-CarboxyAnhydrides and Urethane N-Carboxyanhydrides building blocks for pharmaceutical synthesis. Approximately 60 catalogued NCAs plus custom synthesis on demand.
3. Generic APIs: Sale of Generic Active Pharmaceutical Ingredients with regulatory documentation including Amiodarone HCl, Loperamide HCl, Trimebutine, Econazole nitrate, and others manufactured at cGMP plants.
4. Fine Chemical Intermediates: Fine chemical intermediates in cGMP or non-cGMP grades covering phosgene derivatives, protected and activated aminoacids, chiral building blocks, halogeno-aromatics, and heterocycles.
5. ISODEL® Vitamin E TPGS: Sale of ISODEL® Vitamin E TPGS (Tocophersolan) as pharmaceutical excipient for drug delivery applications. Also offers TPGS analogues with different PEG molecular weights (200, 300, 400, 1500, 2000, 4000 g/mol).
6. Polyamino Acids: GMP polymers and copolymers based on polyamino acids (Poly-L-Lysine, Poly-L-Glutamic acid, Polysarcosine) for drug delivery and polymer conjugates. Services from R&D to GMP manufacturing.
7. Anti-scratch Varnishes: Manufacture and sale of polysiloxane varnishes for anti-scratch coating of organic optical surfaces including ophthalmic and sun glasses, safety glasses.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PMC Isochem is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides custom synthesis and cGMP manufacturing of active pharmaceutical ingredients (APIs), intermediates, excipients, and polymers for drug delivery. It operates three cGMP production sites in France with 240 m3 total reaction capacity, leveraging hazardous chemistry capabilities such as phosgenation, hydrogenation, cryogenic reactions, and halogenation. The company also sells catalog products including Vitamin E TPGS (ISODEL® brand), polyamino acids, N-CarboxyAnhydrides (NCAs), generic APIs, and pharmaceutical intermediates, and recently launched CRO analytical and nanoformulation services.

Product overview

PMC Isochem is a pharmaceutical CDMO (Contract Development and Manufacturing Organization) offering a comprehensive portfolio of products and services. The core offering centers on Custom Development and Manufacturing under cGMP conditions across three French production sites. Key product lines include: Vitamin E TPGS (ISODEL®) - a water-soluble Vitamin E derivative for drug delivery available in multiple molecular weight variants; Polyamino Acids (PAA) manufactured from internally-supplied N-CarboxyAnhydrides; a catalog of ~60 NCAs and UNCAs for peptide synthesis and polymerization; Generic Active Pharmaceutical Ingredients; ~160 pharmaceutical intermediates; and anti-scratch varnishes for optical applications. The company also provides advanced chemical technologies including phosgenation, hydrogenation, halogenation, cryogenic chemistry, and distillation. Recent expansion includes new CRO analytical and nanoformulation services launched under the ISODEL® drug delivery brand umbrella.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom Development and Manufacturing (CDMO) Full-service pharmaceutical CDMO offering custom manufacturing of APIs, intermediates, excipients, and polymers from R&D through commercial scale under cGMP conditions across three production sites in France, serving pharmaceutical companies requiring hazardous chemistry and complex multi-step synthesis.
• Vitamin E TPGS (ISODEL®) Water-soluble derivative of natural Vitamin E used as a pharmaceutical excipient for drug delivery, functioning as emulsifier, solubilizer, absorption enhancer, P-gp inhibitor, hot melt extrusion plasticizer, amorphous solid dispersion stabilizer, and antioxidant; available in multiple PEG molecular weight variants (200, 300, 400, 1500, 2000, 4000 g/mol).
• Polyamino Acids (PAA) GMP polymers and copolymers based on polyamino acids including Poly-L-Lysine, Poly-L-Glutamic acid, and Polysarcosine, used for drug delivery applications including nanotechnologies, polymer conjugates, and targeted delivery systems; manufactured from internal NCA supply chain.
• N-CarboxyAnhydrides (NCA) and UNCAs

Quantifiable outcome

• 10+ years supplying Vitamin E TPGS for FDA approved drugs
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Polypeptide Therapeutic SolutionscoreStrategic or Co-development Partner · 7 March 2018Business and technology collaboration agreement in the field of Cosmetic and Therapeutic Polypeptide. The partnership combines PMC Isochem's NCA technology and GMP manufacturing capabilities with Polypeptide Therapeutic Solutions' expertise in polypeptide therapeutics.

Scale indicators11 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Fareva: Privately held French CDMO with API and drug product manufacturing capabilities across Europe; directly comparable as a France-based pharmaceutical CDMO competing in similar geographies and customer segments.
• Corden Pharma: European-headquartered CDMO (part of ICIG) offering API manufacturing, peptides, lipid excipients, and drug product services; highly comparable to PMC Isochem's mix of small-molecule API, peptide-related NCA chemistry, and excipient offerings.
• Curia (formerly AMRI): Global CDMO providing small-molecule API development and manufacturing, drug product services, and peptides; comparable as a one-stop CDMO with overlapping API, intermediates, and drug delivery capabilities.
• Hovione: Portugal-headquartered pharmaceutical CDMO specializing in small-molecule API manufacturing, hazardous chemistry, particle engineering and drug delivery; directly comparable to PMC Isochem's hazardous-chemistry, small-molecule API, and drug delivery excipient offering for global pharma customers.
• Recipharm: European CDMO (now EQT-owned) with multiple API and drug-product manufacturing sites across Europe; comparable in offering small-molecule API CDMO services, intermediates, and hazardous chemistry to pharma clients.
• Aenova Group: German CDMO offering solid dosage forms, sterile fill-finish and API manufacturing; comparable as a European mid-market pharmaceutical CDMO serving branded and generic drug companies with cGMP production.
• PolyPeptide Group: Swiss-listed CDMO specializing in GMP peptides and peptide APIs; highly comparable given PMC Isochem's NCA/polyamino acid platform serving peptide and polymer-drug developers with similar regulatory and quality requirements.
• Bachem: Swiss-listed CDMO focused on peptides and oligonucleotide APIs; overlaps with PMC Isochem's aminoacid-based chemistry, NCA building blocks, and polymer-drug conjugation services for pharma and biotech.
• Cambrex: US- and Europe-based small-molecule CDMO acquired by Permira; comparable in providing cGMP API and intermediate manufacturing services to pharmaceutical customers, including controlled substance and hazardous chemistry.
• Siegfried Holding: Swiss-listed CDMO offering API and finished drug product manufacturing across multiple sites in Europe and the US; comparable as a Western small-molecule API CDMO serving branded and generic pharma with cGMP production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pmc-isochem

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PMC Isochem